Fertility preservation in the context of cancer care (oncofertility) bridges oncology and reproductive endocrinology. Gonadotoxic cancer treatments, such as alkylating agent chemotherapy, pelvic ionizing radiation, and total body irradiation, pose significant risks to germ cells, leading to premature ovarian insufficiency or permanent azoospermia. The primary objective of a pre-cancer fertility preservation program is to secure viable gametes or reproductive tissues prior to initiating oncologic therapy.

Modern protocols utilize advanced cryopreservation techniques—specifically vitrification—to store mature unfertilized oocytes, fertilized embryos, or testicular and ovarian tissues. For male patients, sperm cryopreservation via masturbation or surgical sperm extraction provides a highly reliable method for preserving reproductive capability. For female patients, random-start ovarian stimulation allows immediate initiation of cycle protocols regardless of menstrual phase, eliminating traditional delays in cancer treatment.

Pre-cancer fertility preservation involves systematic steps based on patient sex and clinical urgency. For females, controlled ovarian stimulation begins immediately upon referral using exogenous gonadotropins (FSH/hMG). Serial transvaginal ultrasound scans and serum estradiol monitoring track follicle development over 10 to 12 days. When mature follicles reach 17–20 mm, maturation is induced using a GnRH agonist or hCG trigger. Transvaginal ultrasound-guided oocyte aspiration is performed 34–36 hours later under conscious sedation. Retrieved oocytes are processed, stripped of cumulus cells, and vitrified or fertilized via intracytoplasmic sperm injection (ICSI) prior to embryo vitrification. For males, ejaculated semen is collected, evaluated for density and motility, mixed with cryoprotectants, and frozen via liquid nitrogen vapor phase. If testicular sperm extraction is required, testicular tissue microdissection is conducted under regional or general anaesthesia.

Participation in a structured pre-cancer fertility preservation program provides well-documented clinical and psychological benefits supported by international registry data:

• Preservation of Biological Parenthood Potential: Enables long-term preservation of genetic material before exposure to DNA-damaging cytotoxic drugs or ionizing radiation.
• Uncompromised Cancer Survival Outcomes: Evidence demonstrates that modern urgent random-start protocols do not delay the onset of cancer treatment or negatively impact overall survival rates (ASCO Guidelines 2018; ASRM Practice Committee 2024).
• Hormone Safety in Estrogen-Sensitive Cancers: Co-administration of aromatase inhibitors (letrozole) during controlled ovarian stimulation maintains serum estradiol at baseline physiological levels, protecting patients with hormone-receptor-positive breast cancer (Lambertini et al., JCO, 2018).
• High Gamete Post-Thaw Survival: Oocyte vitrification protocols yield post-thaw survival rates between 85% and 95%, with fertilization rates comparable to fresh oocyte cycles (ESHRE Guidelines 2020).
• Psychological Resilience: Formal oncofertility counselling and proactive intervention significantly reduce long-term reproductive distress, anxiety, and post-treatment regret in cancer survivors.

Recovery following pre-cancer fertility preservation is structured around rapid physiological stabilization to ensure zero delay in initiating definitive cancer therapies:

• Immediate Recovery (0–48 Hours): Following transvaginal oocyte retrieval or surgical sperm extraction, patients undergo 1–2 hours of clinical observation. Mild pelvic cramping, light vaginal spotting, or minor scrotal discomfort are managed with paracetamol or short-course analgesics. Most patients resume basic activities the following day.
• Short-Term Recovery (3–14 Days): Ovarian enlargement secondary to stimulation resolves as serum hormone levels return to baseline, typically precipitated by a withdrawal bleed occurring 5–10 days post-retrieval (when a GnRH agonist trigger is used). Male patients recover fully from surgical sperm retrieval within 3–7 days.
• Oncologic Clearance: Patients are cleared to begin systemic chemotherapy, immunotherapy, or radiation therapy immediately following physician sign-off, usually within 24 to 72 hours post-procedure.

Pre-cancer fertility preservation addresses the anticipated loss of reproductive potential secondary to gonadotoxic oncologic therapies and surgical interventions. Specific conditions and treatment exposures managed under oncofertility protocols include:

• Chemotherapy-Induced Gonadotoxicity: Exposure to alkylating agents (e.g., cyclophosphamide, busulfan, chlorambucil) that cause double-strand DNA breaks in resting oocytes and testicular stem cells.
• Radiotherapy-Induced Ovarian or Testicular Failure: Pelvic, abdominal, spinal, or total body irradiation exceeding threshold doses (2 Gy to ovaries; 0.6 Gy to testes).
• Surgical Infertility: Indicated radical pelvic surgeries, such as bilateral oophorectomy, radical hysterectomy, or bilateral orchiectomy for gynecologic, urologic, or pelvic malignancies.
• Conditioning Regimens for Hematologic Malignancies: Myeloablative conditioning protocols prior to autologous or allogeneic hematopoietic stem cell transplantation (HSCT).
• Gonadotoxic Non-Malignant Conditions: Autoimmune diseases or hematologic disorders (e.g., severe systemic lupus erythematosus, aplastic anemia) requiring high-dose immunosuppressive or alkylating regimens.

Female preparation requires rapid baseline baseline blood sampling for AMH, FSH, LH, estradiol, and infectious disease screening (HIV, Hepatitis B/C, Syphilis). A transvaginal ultrasound is performed to assess antral follicle count. Patients requiring ovarian stimulation are instructed on self-administration of subcutaneous gonadotropin injections. For hormone-sensitive cancers, co-treatment with daily oral letrozole is initiated concurrently. Male preparation requires screening for infectious diseases and ejaculate abstinence for 2 to 3 days if clinical timing permits. Patients are advised to maintain fluid hydration and refrain from non-steroidal anti-inflammatory drugs (NSAIDs) prior to surgical retrieval procedures.

Common and mild side effects include transient pelvic abdominal discomfort, mild bloating, injection site bruising, and light vaginal spotting. Less common risks include moderate Ovarian Hyperstimulation Syndrome (OHSS), which is minimized through the use of GnRH agonist triggers and antagonist protocols. Rare but serious complications include severe OHSS (<1%), pelvic infection (<0.5%), pelvic vessel bleeding or hematoma (<0.2%), and anaesthetic adverse events. In testicular tissue surgical procedures, risks include scrotal hematoma, wound infection, or localized testicular atrophy (<1%).

Phase 1: Urgent Multidisciplinary Consultation & Diagnostics
Upon cancer diagnosis, the patient is rapidly referred to a reproductive endocrinologist. Baseline evaluation includes reproductive hormone testing (anti-Müllerian hormone [AMH], follicle-stimulating hormone [FSH], estradiol), transvaginal or transabdominal pelvic ultrasound to assess antral follicle count (AFC), or formal semen analysis.

Phase 2: Protocol Selection & Preparation
The clinical team selects an individualized protocol based on oncologic urgency, hormone sensitivity of the tumor, patient age, and pubertal status. For female patients requiring controlled ovarian stimulation, gonadotropin medications are initiated using a random-start protocol, frequently combined with aromatase inhibitors like letrozole in estrogen-sensitive cases.

Phase 3: Retrieval & Processing
Oocyte retrieval is performed under conscious sedation via transvaginal ultrasound-guided needle aspiration. Male patients provide semen samples via masturbation, or undergo testicular sperm extraction (TESE) under local or general anaesthesia. Cryobiology specialists process and vitrify the collected gametes or tissues.

Phase 4: Transition to Oncologic Therapy & Long-Term Storage
Following retrieval, the patient is cleared to begin cancer therapy, typically within 24 to 48 hours. The vitrified material is stored in liquid nitrogen dewars (-196°C) until the patient completes cancer treatment, achieves remission, and desires pregnancy.